137 related articles for article (PubMed ID: 32233032)
1. Integration of VEK-30 peptide enhances fibrinolytic properties of staphylokinase.
Bhando T; Singh S; Hade MD; Kaur J; Dikshit KL
Biotechnol Appl Biochem; 2021 Apr; 68(2):213-220. PubMed ID: 32233032
[TBL] [Abstract][Full Text] [Related]
2. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity--a staphylokinase variant. I. In vitro study.
Szemraj J; Walkowiak B; Kawecka I; Janiszewska G; Buczko W; Bartkowiak J; Chabielska E
J Thromb Haemost; 2005 Oct; 3(10):2156-65. PubMed ID: 16150047
[TBL] [Abstract][Full Text] [Related]
3. Analysis of plasminogen activation by the plasmin-staphylokinase complex in plasma of alpha2-antiplasmin-deficient mice.
Okada K; Ueshima S; Tanaka M; Fukao H; Matsuo O
Blood Coagul Fibrinolysis; 2000 Oct; 11(7):645-55. PubMed ID: 11085285
[TBL] [Abstract][Full Text] [Related]
4. Fibrin-specific fibrinolysis induced by recombinant staphylokinase.
Shishido Y; Matsumoto T; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
Biol Pharm Bull; 1994 Aug; 17(8):1060-4. PubMed ID: 7820108
[TBL] [Abstract][Full Text] [Related]
5. Cloning and expression of a new recombinant thrombolytic and anthithrombotic agent - a staphylokinase variant.
Kowalski M; Brown G; Bieniasz M; Oszajca K; Chabielska E; Pietras T; Szemraj Z; Makandjou-Ola E; Bartkowiak J; Szemraj J
Acta Biochim Pol; 2009; 56(1):41-53. PubMed ID: 19018330
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of a multifunctional staphylokinase variant with reduced reocclusion, produced from salt inducible E. coli GJ1158.
Pulicherla KK; Kumar A; Gadupudi GS; Kotra SR; Rao KR
Biomed Res Int; 2013; 2013():297305. PubMed ID: 23998121
[TBL] [Abstract][Full Text] [Related]
7. Functional properties of a novel mutant of staphylokinase with platelet-targeted fibrinolysis and antiplatelet aggregation activities.
Chen H; Mo W; Zhang Y; Su H; Ma J; Yao R; Zhang S; Ge J; Song H
Eur J Pharmacol; 2007 Jul; 566(1-3):137-44. PubMed ID: 17451675
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel bifunctional mutant of staphylokinase with platelet-targeted thrombolysis and antiplatelet aggregation activities.
Chen H; Mo W; Su H; Zhang Y; Song H
BMC Mol Biol; 2007 Oct; 8():88. PubMed ID: 17919340
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of alpha 2-plasmin inhibitor.
Sakai M; Watanuki M; Matsuo O
Biochem Biophys Res Commun; 1989 Jul; 162(2):830-7. PubMed ID: 2527034
[TBL] [Abstract][Full Text] [Related]
10. A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study.
Szemraj J; Stankiewicz A; Rozmyslowicz-Szermińska W; Mogielnicki A; Gromotowicz A; Buczko W; Oszajca K; Bartkowiak J; Chabielska E
Thromb Haemost; 2007 Jun; 97(6):1037-45. PubMed ID: 17549308
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
12. Enhancing effect of platelets on staphylokinase-mediated clot lysis and plasminogen activation.
Suehiro A; Tsujioka H; Yoshimoto H; Ueda M; Higasa S; Kakishita E
Thromb Res; 1995 Oct; 80(2):135-42. PubMed ID: 8588190
[TBL] [Abstract][Full Text] [Related]
13. Designing a multifunctional staphylokinase variant (SAK-2RGD-TTI) with appropriate thrombolytic activity in vitro.
Faraji H; Soltani F; Ramezani M; Sadeghnia HR; Nedaeinia R; Moghimi Benhangi H; Mashkani B
Biotechnol Lett; 2020 Jan; 42(1):103-114. PubMed ID: 31686286
[TBL] [Abstract][Full Text] [Related]
14. New derivative of staphylokinase SAK-RGD-K2-Hirul exerts thrombolytic effects in the arterial thrombosis model in rats.
Szemraj J; Zakrzeska A; Brown G; Stankiewicz A; Gromotowicz A; Grędziński T; Chabielska E
Pharmacol Rep; 2011; 63(5):1169-79. PubMed ID: 22180359
[TBL] [Abstract][Full Text] [Related]
15. Staphylokinase as a plasminogen activator component in recombinant fusion proteins.
Szarka SJ; Sihota EG; Habibi HR; Wong S
Appl Environ Microbiol; 1999 Feb; 65(2):506-13. PubMed ID: 9925575
[TBL] [Abstract][Full Text] [Related]
16. Involvement of protease inhibitors in staphylokinase-induced fibrin-specific fibrinolysis.
Shishido Y; Sakai M; Kaneda N; Sansawa H; Shimura K; Hashimoto S; Yokokura T
Biol Pharm Bull; 1994 Dec; 17(12):1595-8. PubMed ID: 7735201
[TBL] [Abstract][Full Text] [Related]
17. Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26.
Schlott B; Hartmann M; Gührs KH; Birch-Hirschfeld E; Gase A; Vettermann S; Collen D; Lijnen HR
Biochim Biophys Acta; 1994 Feb; 1204(2):235-42. PubMed ID: 8142464
[TBL] [Abstract][Full Text] [Related]
18. Staphylokinase: fibrinolytic properties and current experience in patients with occlusive arterial thrombosis.
Collen D; Lijnen HR; Vanderschueren S
Verh K Acad Geneeskd Belg; 1995; 57(3):183-96; discussion 196-8. PubMed ID: 7483814
[TBL] [Abstract][Full Text] [Related]
19. Kinetic studies on the plasminogen activation by the staphylokinase-plasmin complex.
Shibata H; Nagaoka M; Sakai M; Sawada H; Watanabe T; Yokokura T
J Biochem; 1994 Apr; 115(4):738-42. PubMed ID: 8089091
[TBL] [Abstract][Full Text] [Related]
20. Novel recombinant thrombolytic and antithrombotic staphylokinase variants with an RGD motif at their N-termini.
He J; Di J; Xu R; Zhao B
Biotechnol Appl Biochem; 2008 May; 50(Pt 1):17-23. PubMed ID: 18039183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
